A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer

Randolph S. Marks; David L. Graham; Jeff A. Sloan; Shauna Hillman; Steven Fishkoff; James E. Krook; Scott H. Okuno; James A. Mailliard; Tom R. Fitch; Ferdinand Addo

doi:10.1097/01.COC.0000020962.25210.6F

A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer

Randolph S. Marks, David L. Graham, Jeff A. Sloan, Shauna Hillman, Steven Fishkoff, James E. Krook, Scott H. Okuno, James A. Mailliard, Tom R. Fitch, Ferdinand Addo

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). Previously untreated patients received this agent at a dosage of 2.5 mg/m² as a 5-minute intravenous infusion for 5 consecutive days every 3 weeks. Between September 1997 and July 1998, 17 patients were accrued in this study. Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC.

Original language	English (US)
Pages (from-to)	336-337
Number of pages	2
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	26
Issue number	4
DOIs	https://doi.org/10.1097/01.COC.0000020962.25210.6F
State	Published - Aug 2003

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/01.COC.0000020962.25210.6F

Cite this

Marks, R. S., Graham, D. L., Sloan, J. A., Hillman, S., Fishkoff, S., Krook, J. E., Okuno, S. H., Mailliard, J. A., Fitch, T. R., & Addo, F. (2003). A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 26(4), 336-337. https://doi.org/10.1097/01.COC.0000020962.25210.6F

Marks, RS, Graham, DL, Sloan, JA, Hillman, S, Fishkoff, S, Krook, JE, Okuno, SH, Mailliard, JA, Fitch, TR & Addo, F 2003, 'A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 26, no. 4, pp. 336-337. https://doi.org/10.1097/01.COC.0000020962.25210.6F

@article{ee8864f218c8495abc2a674f769c4929,

title = "A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer",

abstract = "A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). Previously untreated patients received this agent at a dosage of 2.5 mg/m2 as a 5-minute intravenous infusion for 5 consecutive days every 3 weeks. Between September 1997 and July 1998, 17 patients were accrued in this study. Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC.",

author = "Marks, {Randolph S.} and Graham, {David L.} and Sloan, {Jeff A.} and Shauna Hillman and Steven Fishkoff and Krook, {James E.} and Okuno, {Scott H.} and Mailliard, {James A.} and Fitch, {Tom R.} and Ferdinand Addo",

year = "2003",

month = aug,

doi = "10.1097/01.COC.0000020962.25210.6F",

language = "English (US)",

volume = "26",

pages = "336--337",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer

AU - Marks, Randolph S.

AU - Graham, David L.

AU - Sloan, Jeff A.

AU - Hillman, Shauna

AU - Fishkoff, Steven

AU - Krook, James E.

AU - Okuno, Scott H.

AU - Mailliard, James A.

AU - Fitch, Tom R.

AU - Addo, Ferdinand

PY - 2003/8

Y1 - 2003/8

N2 - A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). Previously untreated patients received this agent at a dosage of 2.5 mg/m2 as a 5-minute intravenous infusion for 5 consecutive days every 3 weeks. Between September 1997 and July 1998, 17 patients were accrued in this study. Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC.

AB - A phase II study of the dolastatin 15 analog LU 103793 was conducted by the North Central Cancer Treatment Group in patients with advanced non-small-cell lung cancer (SCLC). Previously untreated patients received this agent at a dosage of 2.5 mg/m2 as a 5-minute intravenous infusion for 5 consecutive days every 3 weeks. Between September 1997 and July 1998, 17 patients were accrued in this study. Forty-two treatment cycles were administered with relatively modest toxicity. No responses were seen. This agent appears to be inactive in the treatment of advanced non-SCLC.

UR - http://www.scopus.com/inward/record.url?scp=10744230054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744230054&partnerID=8YFLogxK

U2 - 10.1097/01.COC.0000020962.25210.6F

DO - 10.1097/01.COC.0000020962.25210.6F

M3 - Article

C2 - 12902880

AN - SCOPUS:10744230054

SN - 0277-3732

VL - 26

SP - 336

EP - 337

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 4

ER -

A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this